Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2013 by Medtronic Diabetes R&D Denmark.
Recruitment status was Not yet recruiting
Recruitment status was Not yet recruiting
Sponsor:
Medtronic Diabetes R&D Denmark
Information provided by (Responsible Party):
Medtronic Diabetes R&D Denmark
ClinicalTrials.gov Identifier:
NCT01775059
First received: January 21, 2013
Last updated: February 4, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a multi-center, non-randomized, and interventional study in which subjects will use the Integrated sensor and infusion set with MiniLink Transmitter and the Medtronic Paradigm® VEO™ insulin pump (Sensor augmented pump) for 15 days.
The purpose of this study is to collect performance data on the Integrated sensor and infusion set for approximately 15 days, with the intention for each subject to wear 5 sets for 3 days each.
| Condition | Intervention |
|---|---|
|
Diabetes Mellitus Type I Diabetes Mellitus Type II |
Device: Integrated sensor and infusion set. |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Medtronic Diabetes R&D Denmark:
Primary Outcome Measures:
- Accuracy endpoint [ Time Frame: 5 months ] [ Designated as safety issue: No ]Agreement Rate (% within 20%) using VEO Pump
- Safety endpoint [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]Descriptive summary of SAE, Adverse events and Device complaints
Secondary Outcome Measures:
- Accuracy endpoint [ Time Frame: 5 months ] [ Designated as safety issue: No ]Agreement Rate (% within 20%) using re-analyzed Guardian® REAL-Time and Paradigm® REAL-Time algorithm data
Other Outcome Measures:
- Accuracy endpoint [ Time Frame: 5 months ] [ Designated as safety issue: No ]MARD(%), BIAS(mg/dl), MAD(mg/dl) during study
| Estimated Enrollment: | 50 |
| Study Start Date: | March 2013 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Integrated sensor and infusion set. | Device: Integrated sensor and infusion set. |
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subject is 18 years of age or older at time of screening
- Subject has a clinical diagnosis of insulin requiring diabetes, as determined by investigator.
- Subject is currently using a Medtronic Paradigm Sensor Augmented insulin pump and has been so for a minimum of 3 months at time of enrollment.
- Subject has Continuous Glucose Monitoring experience (min 30% of CGM use within the month prior to enrollment).
- Subject has an average of 3 SMBG per day (verified via CareLink) during the month prior to enrollment.
- Subject is willing to wear the study devices for the duration of the study
- Subject is willing to perform frequent (min 7 per day) SMBGs during study device wear
- Subject is willing to keep a short diary during the device wear.
Exclusion Criteria:
- Female subject is pregnant, per urine pregnancy test performed at time of enrollment in women of child bearing age.
- Female subject plans to become pregnant during the course of the study.
- Subject is unable to tolerate tape adhesive in the area of the placement of the study device.
- Subject has any unresolved adverse skin condition in the area of the placement of the study device (e.g. psoriasis, rash, Staphylococcus infection).
- The subject is not deemed to be an appropriate candidate for the study by the investigator for any reason.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01775059
Please refer to this study by its ClinicalTrials.gov identifier: NCT01775059
Contacts
| Contact: Ulrik Pedersen-Bjergaard, MD | ulrik.pedersen-bjergaard@regionh.dk |
Locations
| Denmark | |
| Fredericia Hospital | Recruiting |
| Fredericia, Denmark, 7000 | |
| Contact: Hans Gjessing, MD hans.gjessing@slb.regionsyddanmark.dk | |
| Principal Investigator: Hans Gjessing, MD | |
| Hilleroed Hospital | Recruiting |
| Hilleroed, Denmark, 3400 | |
| Contact: Ulrik Pedersen-Bjergaard, MD ulrik.pedersen-bjergaard@regionh.dk | |
| Principal Investigator: Ulrik Pedersen-Bjergaard, MD | |
| Hvidovre Hospital | Recruiting |
| Hvidovre, Denmark, 2650 | |
| Contact: Kirsten Norgaard, MD kirsten.noergaard@regionh.dk | |
| Principal Investigator: Kirsten Noergaard, MD | |
Sponsors and Collaborators
Medtronic Diabetes R&D Denmark
Investigators
| Principal Investigator: | Ulrik Pedersen-Bjergaard, MD | Hilleroed Hospital |
More Information
| Responsible Party: | Medtronic Diabetes R&D Denmark |
| ClinicalTrials.gov Identifier: | NCT01775059 History of Changes |
| Other Study ID Numbers: | CEP 277 2012102304 |
| Study First Received: | January 21, 2013 |
| Last Updated: | February 4, 2013 |
| Health Authority: | Denmark: Danish Health and Medicines Authority Denmark: The Danish National Committee on Biomedical Research Ethics |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on September 26, 2016